COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00097942
Recruitment Status : Completed
First Posted : December 2, 2004
Last Update Posted : March 5, 2012
Information provided by:
Forest Laboratories

Brief Summary:
Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of schizophrenia. Memantine is an uncompetitive NMDA receptor antagonist. It is hypothesized that adjunctive therapy with memantine will reduce NMDA receptor hyperactivity, improving signal to noise ratio and thereby improving cognitive symptoms.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: memantine HCl Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 138 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment to Atypical Antipsychotics in Schizophrenia Patients With Persistent Residual Symptoms
Study Start Date : August 2004
Actual Primary Completion Date : September 2005
Actual Study Completion Date : September 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Primary Outcome Measures :
  1. Positive and Negative Symptom Scale (PANSS) - Total Score

Secondary Outcome Measures :
  1. Clinical Global Impression - Severity (CGI-S)
  2. PANNS - Positive Score
  3. PANSS - Negative Score
  4. Calgary Depression Scale for Schizophrenia
  5. Brief Assessment of Cognition
  6. Clinical Global Impression - Improvement

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • DSM-IV diagnosed Schizophrenia or schizoaffective disorder who are on a stable antipsychotic regimen with Brief Psychiatric Rating Scale (BPRS) total score greater than or equal to 26 and greater than or equal to 4 on at least one item

Exclusion Criteria:

  • Secondary diagnosis of Bipolar I disorder
  • Suicidal history
  • Organic brain disease
  • Dementia
  • History of substance abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00097942

Layout table for location information
United States, California
Synergy Clinical Research
National City, California, United States, 91950
VA San Diego Healthcare System
San Diego, California, United States, 92161
United States, Florida
University of Miami Jackson Memorial Hospital
Miami, Florida, United States, 33136
United States, Iowa
University of Iowa Psychiatric Research
Iowa City, Iowa, United States, 52242
United States, Maryland
CBH Health, LLC
Rockville, Maryland, United States, 20850
United States, Missouri
Metropolitan Psychiatric Center
St. Louis, Missouri, United States, 63112
United States, New Hampshire
Dartmouth Hitchcock Medical School
Lebanon, New Hampshire, United States, 03755
United States, New York
Nathan Kline Institute
Orangeburg, New York, United States, 10962
United States, North Carolina
Duke University John Umstead Hospital
Butner, North Carolina, United States, 27509
UNC - Chapel Hill, Clinical Research Unit
Raleigh, North Carolina, United States, 27699-3601
United States, Ohio
University of Cincinnati Medical Science Building
Cincinnati, Ohio, United States, 45267-0559
United States, Texas
University Hills Clinical Research
Irving, Texas, United States, 75062
Medication Research Clinic
San Antonio, Texas, United States, 78207
Sponsors and Collaborators
Forest Laboratories
Layout table for additonal information Identifier: NCT00097942    
Other Study ID Numbers: MEM-MD-29
First Posted: December 2, 2004    Key Record Dates
Last Update Posted: March 5, 2012
Last Verified: March 2012
Keywords provided by Forest Laboratories:
adjunctive therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents